Literature DB >> 16465821

[Management of cutaneous leishmaniasis in adults and children].

P Minodier1, G Noël, P Blanc, M Uters, K Retornaz, J M Garnier.   

Abstract

Cutaneous leishmaniasis can present a variety of clinical features and courses. The causative Leishmania species is an important prognostic factor in immunocompetent patients. Local treatment modalities including topical paromomycin, cryotherapy, localized controlled heat, carbon dioxide laser therapy, or intralesional meglumine antimoniate can be effective against Leishmania major or Leishmania tropica. Oral fluconazole may be a second-line treatment. Parenteral antimonials are useful for persistent or recurrent Old World leishmaniasis. For New World leishmaniasis, parenteral antimonials represent the first-line treatment in all forms except those caused by Leishmania guyanensis in which pentamidine is preferable. Liposomal amphotericin B appears to be effective for treatment of cutaneous leishmaniasis but further study will be needed. Results using oral Miltefosine are promising against Indian kala-azar (Leishmania donovani) but disappointing against South American leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16465821

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  2 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.

Authors:  Pouran Layegh; Sara Rahsepar; Amir Ali Rahsepar
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.